Breadcrumb
Home - McKesson Canada
Advancing Health Outcomes for All
Touching Virtually Every Aspect of Health
As a diversified healthcare leader, our solutions help patients access life-changing therapies, whether because we deliver a third of all medications in Canada, consult with patients at our pharmacies, or partner with members and stakeholders of the healthcare industry. We do all this and much more as we pursue our purpose to advance health outcomes for all.




Advancing Health Outcomes for All
Touching Virtually Every Aspect of Health
As a diversified healthcare leader, our solutions help patients access life-changing therapies, whether because we deliver a third of all medications in Canada, consult with patients at our pharmacies, or partner with members and stakeholders of the healthcare industry. We do all this and much more as we pursue our purpose to advance health outcomes for all.
Distribution
Biopharma & Provider Solutions
Retail Pharmacy Solutions
Automation Technology Solutions
mckca_homePressReleasenew


SPOTLIGHT ON:
Rare Disease Drugs In Canada: Considerations For Equitable Access
Ensuring comprehensive, timely and equitable access to medication for rare diseases is a significant public policy priority for the Government of Canada. McKesson Canada is proud to contribute to the public policy conversation around this national strategy, building on its experience with patient support programs, pharmaceutical distribution, and specialty pharmacy services.


SPOTLIGHT ON:
Rare Disease Drugs In Canada: Considerations For Equitable Access
Ensuring comprehensive, timely and equitable access to medication for rare diseases is a significant public policy priority for the Government of Canada. McKesson Canada is proud to contribute to the public policy conversation around this national strategy, building on its experience with patient support programs, pharmaceutical distribution, and specialty pharmacy services.
Press Releases
McKesson Canada Expands Patient Access to Cutting-Edge Radioligand Therapy in Ontario
Mississauga, Ontario (March 24, 2025) – McKesson Canada is pleased to announce it has started treating patients with radioligand therapy (RLT) at its newest INVIVA infusion clinic in Toronto, the first time this groundbreaking treatment has been available to patients outside of a hospital setting in Ontario.
"By offering radioligand therapy at INVIVA, we are expanding access to this transformative treatment for patients across the province, while also reinforcing our commitment to advancing patient care," says Dimitris Polygenis, President, Specialty Health, McKesson Canada.
Radioligand therapy represents a breakthrough in nuclear medicine, offering a targeted approach that can significantly improve outcomes for patients with various forms of cancer. By delivering radiation directly to cancer cells, RLT minimizes impact on healthy tissue, resulting in a more precise and effective treatment.
The organization has invested extensively in the infrastructure and certification needed to deliver nuclear medicine safely and effectively. Staff have undertaken comprehensive training, and the clinic has been licensed by the Canadian Nuclear Safety Commission (CNSC), which requires adherence to rigorous quality assurance standards.
“While only a few RLT drugs are currently available in Canada – primarily to treat certain forms of cancer, such as prostate and neuroendocrine tumours – we know this is a rapidly evolving area of medicine,” says Lee Steele, Vice President, INVIVA & Chief Nursing Officer, McKesson Canada. “We felt it was important to invest in building a clinic that was capable of delivering these cutting-edge treatments in order to improve health outcomes for patients in Ontario.”
For more information about RLT at INVIVA’s newest clinic, visit inviva.ca/radioligand-therapy.
About INVIVA
Established in 2013, today INVIVA is Canada's largest private infusion network with 68 clinics that provide patients with specialized therapy in a caring and compassionate setting. INVIVA experts work directly with manufacturers to bring specialty therapies and nursing services to patients in need while improving access. They engage with health care providers to improve the patient experience and make it easier for everyone to manage complex diseases. Its team of highly trained seasoned nurses help manage various therapeutic areas, including gastroenterology, rheumatology, geriatrics, pediatrics, and more. In 2023, INVIVA was awarded accreditations in Cancer Care, Ambulatory Care, Home Care Services, Leadership, Infection Prevention and Control, and Medication Management making it the first national private infusion network with accreditation.
About McKesson Canada
McKesson Canada is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of healthcare at www.McKesson.ca.
Media contact:
Sybil Millar
Senior Advisor, Media Relations and External Communications, McKesson Canada
media@mckesson.ca
McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
December 31, 2024 (IRVING, Texas) – McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms.
Additional details related to the divestiture can be found on the company’s Investor Relations website.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
Cautionary Statements
Except for historical information, statements in this press release regarding McKesson’s capital deployment, investment and growth platforms constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unsuccessful in achieving our strategic growth objectives; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
Contacts
Investor Relations
Rachel Rodriguez
469-260-2556
Rachel.Rodriguez@McKesson.com
Media
Media@mckesson.ca
Princess Margaret Cancer Centre and McKesson Canada partner to elevate best practices for cancer treatment in community infusion clinics
Toronto, ON (October 24, 2024) – Princess Margaret Cancer Centre, part of University Health Network in Toronto, has partnered with McKesson Canada to implement best practices for the delivery of high-quality care to cancer patients who receive treatment in the organization’s network of community infusion clinics.
As part of their cancer journey, some oncology patients use independent, community-based infusion clinics, which can offer a wider variety of treatment options for patients and provide access to leading edge medicines. This partnership will benefit patients and ensure they receive the same level of seamless, high-quality care at McKesson Canada’s INVIVA clinics as they do at Princess Margaret.
To date, formal relationships between community infusion clinics and cancer centres have been limited. Before launching the partnership, Princess Margaret conducted a comprehensive inspection of McKesson Canada’s oncology services, which are accredited by Accreditation Canada, including its infusion clinics and pharmacy at its central Toronto location. With the partnership now in place, Princess Margaret and McKesson Canada look forward to working together to align quality standards.
About Princess Margaret Cancer Centre
The Princess Margaret Cancer Centre has gained an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is part of University Health Network in Toronto. For more information: www.theprincessmargaret.ca
About McKesson Canada
McKesson Canada is a diversified healthcare services leader dedicated to advancing health outcomes for patients. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver products, services and insights to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of healthcare at www.McKesson.ca.
For media inquiries:
The Princess Margaret Cancer Centre
Marina Jimenez
McKesson Canada
Sybil Millar